Pharma Front Group Hosted House Staffers at Luxury Resort Before BBB Vote
Days before the House voted on the Build Back Better Act, Center Forward hosted dozens of congressional staffers to discuss policy issues with lobbyists.
Health
Page 3
Health Insurance and Pharma Lobbyists Max Out to the Dem Party
The Senate braces for a showdown over expanding Medicare to include dental and vision benefits after healthcare industry lobbyists have bundled six-figure donations for Democrats’ campaign arms.
Schumer Took a $66k Bundle of Checks From the Health Insurance Industry’s Top Lobbyist
The bundle was given as the health insurance industry was lobbying against Medicare dental, vision, and hearing coverage being included in the Build Back Better Act.
Top House Dem Buys Stock in Pharma Companies and Defense Contractors
House Budget Chair John Yarmuth is a frequent stock trader who recently purchased shares in companies that are lobbying against the Democrats' budget plan.
More and More Medicare Money is Flowing to Private Equity
Recent academic studies have found that private equity investment is rushing in to for-profit healthcare companies, but patients may not benefit.
News Outlet Founded by Blue Dog Dem Operatives Promotes Big Pharma's Lobbying Aims
Leaders of a centrist advocacy group with funding from the pharmaceutical industry founded outlet The Well News and have editorial input on its promoted posts.
Health Care and Hedge Fund Execs Fundraise for Gottheimer as He Leads Moderate Crusade Against Reconciliation Bill
Rep. Josh Gottheimer (D-N.J.) is the unofficial leader of a bloc of conservative Democrats opposing the up to $3.5 trillion budget reconciliation package.
Corporate-Backed Blue Dogs Threaten Democrats’ Budget Plan
Facing health care and climate crises, a group of six conservative House Democrats are seeking to pump the brakes on the largest federal investments in decades.
U.S. Has Worst Health Care Despite Spending the Most On It
Half of lower-income Americans face cost barriers to getting health care, according to a new report from the Commonwealth Fund.
Pharma Companies Spend Billions More on Stock Buybacks Than Developing Drugs, House Report Finds
The largest drugmakers spent $56 billion more on stock buybacks and dividends than on research and development from 2016 to 2020, according to a new House committee report.